@article{08b14c3bb8c5414ba91d8f72f0f1a5b8,
title = "Treatment of dementia with lewy bodies",
abstract = "Dementia with Lewy bodies (DLB) is a multisystem disorder with diverse disease expression. A treatment regime restricted to the cognitive aspects of the disease does no favor to patients. Instead, patients should be educated to recognize the symptoms of this multisystem involvement. There are no treatments that slow the progression of disease, but symptomatic treatments can be effective. When thinking about treatment, we find it useful to divide the symptoms and signs into five categories: (a) cognitive features, (b) neuropsychiatric features, (c) motor dysfunction, (d) autonomic dysfunction, and (e) sleep dysfunction. Clinicians, funding bodies and industry are increasingly recognizing the importance of this common and debilitating disease.",
keywords = "Antipsychotic, Cholinesterase inhibitors, Dementia with Lewy bodies, Dysautonomia, Parkinson's disease dementia, REM sleep behavior disorder, Treatment",
author = "Boot, {Brendon P.} and McDade, {Eric M.} and McGinnis, {Scott M.} and Boeve, {Bradley F.}",
note = "Funding Information: Brendon P. Boot has served as an investigator for clinical trials sponsored by Pfizer, Janssen Pharmaceutica, and Bristol-Myers Squibb. Eric M. McDade has served as a consultant for the Dominantly Inherited Alzheimer Network Therapeutic Trial Unit, has received grant support from the National Institutes of Health, The Pittsburgh Foundation, and the University of Pittsburgh Alzheimer Disease Research Center, has received honoraria from the Alzheimer Association, and has received royalties from UptoDate. Scott M. McGinnis has served as an investigator for clinical trials sponsored by Pfizer, Janssen Pharmaceutica, Bristol-Myers Squibb, Mediviation, TauRx, and Allon Therapeutics. Bradley F. Boeve has served as an investigator for clinical trials sponsored by Cephalon, Allon Pharmaceuticals and GE Healthcare. He receives royalties from the publication of a book entitled Behavioral Neurology of Dementia (Cambridge Medicine, 2009). He has received honoraria for development of educational presentations from the American Academy of Neurology. He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from the National Institute on Aging (P50 AG016574, U01 AG006786, RO1 AG032306, RO1 AG041797) and the Mangurian Foundation.",
year = "2013",
month = dec,
doi = "10.1007/s11940-013-0261-6",
language = "English (US)",
volume = "15",
pages = "738--764",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "6",
}